Tsui D, Aisner DL, Nijmeh H, Bao L, Menter A, Camidge R. Tumor shrinkage with combination of Alectinib and Trastuzumab in a patient with ALK-rearranged non-small cell lung cancer harboring HER2-amplification as an acquired resistance mechanism to ALK inhibitor therapy. Clin Lung Cancer. 2022 Mar;23(2):e99-e103.